Overview of the 2017 KDIGO CKD-MBD Update: Practice Implications for Adult Hemodialysis Patients  Judith Beto, PhD, RDN, FAND, Nisha Bhatt, MD, Teresa.

Slides:



Advertisements
Similar presentations
Uncontrolled secondary hyperparathyroidism in a haemodialysis patient Jordi Bover, MD, PhD Fundació Puigvert Barcelona, Spain © Springer Healthcare, a.
Advertisements

Volume 68, Pages S24-S28 (July 2005)
Volume 79, Pages S3-S8 (April 2011)
KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder.
Volume 67, Pages S1-S7 (June 2005)
Can Pizza Fit in to the Renal Diet
Mineral and bone disorders in chronic kidney disease and end-stage renal disease patients: new insights into vitamin D receptor activation  Jordi Bover,
Vitamin D Insufficiency
KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder.
Electrolyte Disorders Associated With Cancer
Volume 73, Issue 1, Pages 3-5 (January 2008)
Cristiane Moraes, PhD, Denis Fouque, PhD, Ana Claudia F
Can Pizza Fit in to the Renal Diet
Is it Important to Prevent and Treat Protein-Energy Wasting in Chronic Kidney Disease and Chronic Dialysis Patients?  Bereket Tessema Lodebo, MD, MPH,
Fibroblast Growth Factor 23 and CKD Prognosis
American Journal of Kidney Diseases 
Jiak Chin Koh, RD, MSc, Winphia Koo, RD, CDE 
Rosa K. Hand, MS, RDN, LD, Jerrilynn D. Burrowes, PhD, RD, CDN 
Phosphorus: Another Devil in Our Diet?
FGF23 or PTH: which comes first in CKD ?
MyPlate for Healthy Eating With Chronic Kidney Disease (MyPlate Education for Patients With Chronic Kidney Disease Receiving Hemodialysis and Peritoneal.
Chinese Nutrition Educational Materials for Renal Patients
Debra Memmer, MS, RD, LD  Journal of Renal Nutrition 
Tilman B. Drüeke, Ziad A. Massy  Kidney International 
FGF23–parathyroid interaction: implications in chronic kidney disease
Medical Nutrition Therapy for Chronic Kidney Disease Improves Biomarkers and Slows Time to Dialysis  Desirée de Waal, MS, RD, CD, FAND, Emily Heaslip,
Determinants of Plasma Adiponectin Levels in Nondiabetic Subjects With Moderate to Severe Chronic Kidney Disease  Luis F. Ramos, MD, Ayumi Shintani, PhD,
Janeen B. León, MS, RD, LD, Catherine M
Reassessment of the care of the patient with chronic kidney disease
Volume 79, Pages S24-S27 (April 2011)
Volume 79, Pages S3-S8 (April 2011)
M. Fukagawa, S. Nakanishi, J.J. Kazama  Kidney International 
Artificial Nutritional Support in Chronic Hemodialysis Patients: A Narrative Review  Maurizio Bossola, MD, Luigi Tazza, MD, Stefania Giungi, MD, Fausto.
Comparison of Subjective Global Assessment and Protein Energy Wasting Score to Nutrition Evaluations Conducted by Registered Dietitian Nutritionists in.
Chapter 3: Management of progression and complications of CKD
Assessing “Low-Carb” Products
Janeen B. León, MS, RD, LD, Catherine M
2005 NKF clinical meetings abstracts
Nutritional Considerations for Dialysis Vegetarian Patients, Part One
Nutritional Considerations for Dialysis Vegetarian Patients, Part Two
Risk Factors for Hypovitaminosis D in Nondialyzed Chronic Kidney Disease Patients  Vilani Figuiredo-Dias, MS, Lilian Cuppari, PhD, Miriam Ghedini Garcia-Lopes,
Cristiane Moraes, PhD, Denis Fouque, PhD, Ana Claudia F
Dietary habits and counseling focused on phosphate intake in hemodialysis patients with hyperphosphatemia  Adamasco Cupisti, MD, Claudia D’Alessandro,
Effect of Aggressive Osteodystrophy Management on Clinical Outcomes in Stage 5 Chronic Kidney Disease  Laura Byham-Gray, PhD, RD, Tammy Drasher, RD, LDN,
Graphic Interpretation of Serum Parathyroid Hormone, Calcium, and Phosphorus Values in Primary Hyperparathyroidism  Pai C. Kao, Ph.D., Edward G. Lufkin,
Volume 79, Pages S20-S23 (April 2011)
Use of vitamin D in chronic kidney disease patients
Volume 79, Issue 1, Pages (January 2011)
Chinese Nutrition Educational Materials for Renal Patients
Sevelamer Hydrochloride Binds Phosphate Released from Phytate in Chicks Fed 1α- Hydroxy Cholecalciferol  Elizabeth A. Bobeck, BS, Katie M. Meyer, MS, Christian.
Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism 
Volume 68, Pages S24-S28 (July 2005)
Kidney-Friendly Label Reading for Chronic Kidney Disease Shoppers
The DOPPS Practice Monitor for US Dialysis Care: Potential Impact of Recent Guidelines and Regulatory Changes on Management of Mineral and Bone Disorder.
Joanne Cooke, MS, RDN, LD, CSR, FAND  Journal of Renal Nutrition 
Volume 87, Issue 3, Pages (March 2015)
Volume 75, Issue 9, Pages (May 2009)
Development and progression of secondary hyperparathyroidism in chronic kidney disease: lessons from molecular genetics  William G. Goodman, L.D. Quarles 
Fibroblast growth factor 23: the making of a hormone
International and Racial Differences in Mineral and Bone Disorder Markers and Treatments Over the First 5 Years of Hemodialysis in the Dialysis Outcomes.
Recent developments in the management of secondary hyperparathyroidism
The ins and outs of phosphate homeostasis
Diagram of the mechanisms involved in limiting the ability of the kidney to maintain the levels of 1,25-dihydroxyvitamin D in chronic kidney disease (CKD).
Assessing “Low-Carb” Products
CKD Is a Global Burden With Major Implications
The Importance of Sodium Restrictions in Chronic Kidney Disease
Ronen Levi, Justin Silver  Kidney International 
What Should a Guideline Panel Do When Evidence Is Inconclusive
Volume 86, Issue 2, Pages (August 2014)
Volume 64, Pages S131-S136 (November 2003)
Presentation transcript:

Overview of the 2017 KDIGO CKD-MBD Update: Practice Implications for Adult Hemodialysis Patients  Judith Beto, PhD, RDN, FAND, Nisha Bhatt, MD, Teresa Gerbeling, MS, RD, CSR, Chhaya Patel, MA, RDN, CSR, Debra Drayer, PharmD  Journal of Renal Nutrition  Volume 29, Issue 1, Pages 2-15 (January 2019) DOI: 10.1053/j.jrn.2018.05.006 Copyright © 2018 The Authors Terms and Conditions

Figure 1 Pathophysiological mechanism of chronic kidney disease-mineral bone disorders. 1,25 D, 1-α-hydroxylation of 25-hydroxy vitamin D; Ca++, ionized calcium; FGF-23, fibroblast growth factor 23; PTH, parathyroid hormone. Only change was PTH lettering to white so could be seen more clearly. Journal of Renal Nutrition 2019 29, 2-15DOI: (10.1053/j.jrn.2018.05.006) Copyright © 2018 The Authors Terms and Conditions

Figure 2 Current SHPT therapies with complimentary effects on PTH, phosphorus, and calcium. PTH, parathyroid hormone; SHPT, secondary hyperparathyroidism. Journal of Renal Nutrition 2019 29, 2-15DOI: (10.1053/j.jrn.2018.05.006) Copyright © 2018 The Authors Terms and Conditions

Figure 3 (Clinical Scenario Box 1). Clinical practice example for SHPT general management. CKD-MBD, chronic kidney disease-mineral bone disorder; labs, laboratory values; MBD, mineral bone disorder; prn, when necessary; PTH, parathyroid hormone; SHPT, secondary hyperparathyroidism. Journal of Renal Nutrition 2019 29, 2-15DOI: (10.1053/j.jrn.2018.05.006) Copyright © 2018 The Authors Terms and Conditions

Figure 4 (Clinical Scenario Box 2). Clinical practice example for phosphorous and phosphate management. Journal of Renal Nutrition 2019 29, 2-15DOI: (10.1053/j.jrn.2018.05.006) Copyright © 2018 The Authors Terms and Conditions

Figure 5 (Clinical Scenario Box 3). Clinical practice example for calcium management. CKD-MBD, chronic kidney disease-mineral bone disorder; IV, intravenous; labs, laboratory values; MBD, mineral bone disorder; QD, once a day; PTH, parathyroid hormone; SHPT, secondary hyperparathyroidism; TID, 3 times a day; TIW, 3 times a week. Journal of Renal Nutrition 2019 29, 2-15DOI: (10.1053/j.jrn.2018.05.006) Copyright © 2018 The Authors Terms and Conditions

Figure 6 (Clinical Scenario Box 4). Clinical practice example for dialysate calcium management. CKD, chronic kidney disease; HD, hemodialysis; labs, laboratory values; TID, 3 times a day; TIW, 3 times a week. Journal of Renal Nutrition 2019 29, 2-15DOI: (10.1053/j.jrn.2018.05.006) Copyright © 2018 The Authors Terms and Conditions

Figure 7 (Clinical Scenario Box 5). Clinical practice example for PTH management. CKD, chronic kidney disease; IV, intravenous; labs, laboratory values; PI, prescribing information; PTH, parathyroid hormone; TID, 3 times a day; TIW, 3 times a week. Journal of Renal Nutrition 2019 29, 2-15DOI: (10.1053/j.jrn.2018.05.006) Copyright © 2018 The Authors Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2024 SlidePlayer.com. Inc. All rights reserved.